Fletikumab
Fletikumab
Fletikumab (pronounced: fle-ti-ku-mab) is a monoclonal antibody designed for the treatment of rheumatoid arthritis and other autoimmune diseases.
Etymology
The name "Fletikumab" follows the World Health Organization's guidelines for the nomenclature of monoclonal antibodies. The suffix "-mab" indicates that it is a monoclonal antibody, while the infix "-ti-" suggests that it is intended for the immune system.
Usage
Fletikumab is used in the treatment of rheumatoid arthritis, a chronic inflammatory disorder affecting many joints, including those in the hands and feet. It is also being studied for use in other autoimmune diseases, where the body's immune system mistakenly attacks the body's own cells.
Mechanism of Action
Fletikumab works by binding to and inhibiting the activity of a specific protein in the body that plays a key role in causing inflammation and joint damage in people with rheumatoid arthritis.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Rheumatoid arthritis: A chronic inflammatory disorder affecting many joints, including those in the hands and feet.
- Autoimmune diseases: Diseases in which the body's immune system attacks healthy cells.
See Also
External links
- Medical encyclopedia article on Fletikumab
- Wikipedia's article - Fletikumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski